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Multiple sclerosis (MS) is a chronic, potentially 
disabling, immune-mediated infl ammatory demyeli-
nating disease of the central nervous system (CNS). 
Th e pathophysiology of MS, though not fully under-
stood, includes early infl ammatory cell infi ltration of 
the CNS aff ecting primarily the white matter, demy-
elination and axonal damage, resulting in permanent 
clinical disability, which occurs at an early stage of the 
disease [1]. Th us, focal CNS infl ammation, demyeli-
nation and axonal loss are typical features although 
pathologically there is heterogeneity [1]. 
MS is a challenging disease to treat, not least be-
cause of its signifi cant heterogeneity and unpredict-
able clinical course. Parameters of the early disease 
course such as brain magnetic resonance imaging 
(MRI) data and the number of clinical attacks in the 
fi rst 2-10 years tend to predict long term outcome in 
MS patients [2, 3]. Th is evidence provides a rationale 
for early intervention with disease modifying thera-
pies (DMTs), aiming to reduce relapses and resulting 
residual disabilities, and to prevent or delay the onset 
of progressive disability. 
Conventional DMTs in multiple sclerosis
Immunomodulatory agents, which became available 
from the early 1990s, aim to prevent relapses, minimise 
disability and reduce disability progression (particu-
larly relapse-related disability). Th e immunomodulatory 
agents interferon (IFN)-beta 1a, IFN-beta 1b and glati-
ramer acetate (GA) are fi rst-line therapy in MS [4]. 
Pivotal phase III studies of IFN-beta and GA, 
conducted as 2-year, double-blinded, randomized, 
placebo-controlled, multicentre trials, have all dem-
onstrated a signifi cant reduction in relapse rate (by 
approximately 30%) and improvement in brain MRI 
measures of disease activity in relapsing-remitting 
(RR) MS patients [4]. Additionally, in these studies, 
treatment of MS with IFN-beta and GA produced a 
benefi cial eff ect on MRI measures of disease severity 
such as T2 disease burden and modestly slowed sus-
tained disability progression. 
While both IFN-beta 1a and IFN-beta 1b dem-
onstrated signifi cant reductions of the attack rates and 
MRI burden of disease in secondary progressive (SP) 
MS patients [4], the European trial with IFN-beta 
1b was the only study to show a signifi cant reduction 
in the confi rmed 1-point Expanded Disability Status 
Scale (EDSS) progression rate in this setting [5]. 
Some head-to-head trials and long-term follow-up 
data have since added to the evidence on DMTs in the 
RRMS setting. Th e results for standard doses of IFN-
beta 1a im compared to IFN-beta 1a sc and IFN-beta 
1b sc in the EVIDENCE [6] and INCOMIN trials 
[7], respectively, are believed to refl ect a dose-response 
eff ect. 
Trials comparing GA with IFN-beta 1b sc (BE-
YOND, BETAFERON Effi  cacy Yielding Outcomes 
of a New Dose [8]; BECOME, BETASERON ver-
sus COPAXONE in MS with triple-dose gadolinium 
and 3T MRI Endpoints [9]) and IFN-beta 1a sc (RE-
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GARD, REBIF 44 μg versus GA in Relapsing MS 
Disease [10]) quite unexpectedly showed lower relapse 
rates than in the pivotal trials with these agents, but 
did not reveal clinically important diff erences in ef-
fi cacy between the IFN-beta treatments and GA.
 To determine whether early treatment with DMTs 
(IFN-beta or GA) following a clinically isolated syn-
drome (CIS), the fi rst demyelinating clinical event 
suggestive of MS, can delay the second clinical event 
and therefore a diagnosis of clinically defi nite MS 
(CDMS), four large-scale placebo-controlled clini-
cal trials were conducted [4, 11]. All these trials have 
shown a consistent reduction in the cumulative prob-
ability of developing CDMS in CIS patients receiving 
early treatment with these conventional DMTs, and 
extension studies and long-term follow up data have 
since demonstrated the long-term benefi ts in this set-
ting as well [12,13].
Neither IFN-beta [14] nor GA [15] have shown 
effi  cacy in primary progressive MS.
Long-term adherence to disease-modifying ther-
apy in RRMS is associated with improved patient 
outcomes, including a reduced risk of relapse and a 
better preserved quality of life. However, the unpre-
dictable nature of the disease, even when it is being 
treated, may make it diffi  cult to convince patients of 
the importance of treatment adherence. A number of 
studies have attempted to pinpoint factors that aff ect 
adherence. Nursing interventions that address some 
of these factors may improve adherence and, thus, the 
disease course for a variety of RRMS patients. Nurs-
ing interventions, including telephone counseling and 
motivational interview techniques, can improve ad-
herence.
Second-line DMTs in multiple sclerosis
Despite notable advances in the understanding of 
MS and the availability of afore-mentioned several 
treatment options, there is a need for therapies that 
are more eff ective, safe, convenient, and well tolerat-
ed. Further development of DMT in MS has rapidly 
evolved over the last few years and continues to do so, 
leading to the additions to the treatment armamen-
tarium, comprising recently introduced antibody na-
talizumab and more recently, the sphyngosin-1-phos-
phate receptor modulator fi ngolimod. Because data 
on these new therapies continue to emerge, nurses 
will play a pivotal role in educating patients regarding 
the benefi ts and risks of potential treatments and in 
monitoring patients for response, safety, tolerability, 
and adherence. 
Natalizumab (TYSABRI®) is a recombinant, 
humanized monoclonal antibody directed against 
the α4-integrin, a component of Very Late Antigen 
(VLA)-4 on the surface of lymphocytes. Natalizum-
ab blocks the interaction of VLA-4 with its ligand 
vascular-cell adhesion molecule 1 (VCAM-1) on the 
surface of vascular endothelial cells in brain and spi-
nal cord blood vessels, thus reducing the adhesion and 
migration of lymphocytes into the brain and thereby 
reducing infl ammation [16].
Th e safety and effi  cacy of natalizumab in the treat-
ment of RRMS was evaluated in two phase III stud-
ies. Th e fi rst study compared natalizumab vs. placebo 
(AFFIRM) and the second natalizumab plus interfer-
on-beta 1a (Avonex) vs. placebo plus Avonex (SEN-
TINEL) [17, 18]. In the AFFIRM study, natalizumab 
(300 mg in intravenous infusion, once every 4 weeks) 
reduced the rate of clinical relapse at 1 year by 68% 
and the risk of 24 week sustained progression of dis-
ability by 54% over 2 years [17]. Th e accumulation of 
new or enlarging hyperintense lesions over two years, 
as detected by T2-weighted MRI, was reduced by 
83% for natalizumab versus placebo [17]. In the 2-year 
SENTINEL study, add-on natalizumab resulted in 
a 24% reduction in the relative risk of sustained dis-
ability progression compared to IFN-beta 1a alone, a 
reduction in annualized relapse rates of 54% and 55%, 
respectively, at 1 and 2 years, and an 83% reduction in 
new or enlarging lesions on T2-weighted MRI. Na-
talizumab eff ects were sustained with low annualised 
relapse rates and stable disability scores confi rmed in 
the open-label STRATA extension study evaluating 
the long-term safety of natalizumab in participants of 
these and other controlled studies. 
Convincing data on relapse rate reduction after one 
year in the AFFIRM study resulted in accelerated ap-
proval of the agent in the US at the end of 2004. Only 
three months later, in 2005, natalizumab was with-
drawn from the market when two fatal cases of pro-
gressive multifocal leucoencephalopathy (PML), were 
reported in patients receiving natalizumab and IFN-β 
in the SENTINEL trial [19,20]. A subsequent safety 
evaluation of the drug estimated the risk of PML to 
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be 1 in 1000 (0.1%) over an 18-month treatment pe-
riod [21]. Following this report, natalizumab was re-
approved as monotherapy for active relapsing MS in 
2006 by the EMEA with a number of restrictions [4]. 
Th e approval label currently represents a compromise 
between the expected benefi t of natalizumab in active 
relapsing disease and the potential risk of this therapy 
with emphasis on the greatest possible patient safety. 
Up to November 2010, there were on the whole 75 
confi rmed natalizumab-associated PML cases [22]. 
Finally, it is assumed now that benefi cial eff ects 
outweigh the risk of developing PML, as supported by 
a recent risk-benefi t analysis [23]. Th erefore, accord-
ing to the current scientifi c information, natalizumab 
is indicated as a “disease-modifying monotherapy of 
highly active relapsing MS” for the following patient 
groups [4]: 1) patients showing high levels of disease 
activity despite treatment with an IFN- beta prepa-
ration, or 2) untreated/treatment-naïve patients with 
rapidly progressing RRMS (at least two serious re-
lapses per year). Th e Multiple Sclerosis Th erapy Con-
sensus Group (MSTCG) recommends that patients 
with RRMS not responding to immunosuppressive 
drugs can be switched to natalizumab after consid-
ering the risk-benefi t ratio and only after at least a 
3-month drug-free interval following azathioprine-
equivalent drugs and after a longer interval (up to 6 
months) following MX (expert opinion) [4]. However, 
no defi nitive data are available yet on the safe time 
intervals.
Fingolimod, a synthetic analogue of the immu-
nosuppressive fungal metabolite myriocin [24], is a 
sphingosin-1-phosphate (S1P) receptor modulator for 
once daily oral administration. Fingolimod binding 
to S1P receptors on lymphocytes prevents their egress 
from lymph nodes, resulting in a dose-related reduc-
tion in the number of circulating lymphocytes and 
a reduced infi ltration of autoaggressive lymphocytes 
into the central nervous system. 
For the 24-month phase III FREEDOMS study, 
RRMS patients were randomized to receive oral fi n-
golimod at doses of 0.5 mg or 1.25 mg daily or place-
bo [25]. Th e annualized relapse rate was signifi cantly 
lower with both 0.5 mg and 1.25 mg fi ngolimod (0.18 
and 0.16, respectively) than with placebo (0.40); this 
relative reduction of about 58% for fi ngolimod groups 
was seen in both treatment-naïve patients and patients 
previously treated with DMTs. Compared to placebo, 
patients on fi ngolimod also showed a reduced risk of 
disability progression and a benefi t in MRI-related ef-
fi cacy end points, with no signifi cant diff erences in 
effi  cacy between the two fi ngolimod doses. 
In the recently completed 12-month, phase III 
controlled trial (TRANSFORMS), a total of 1292 
patients with active RRMS were randomized to 0.5 
mg or 1.25 mg daily oral Fingolimod or 30 μg once-
weekly intramuscular IFN-beta 1a (AVONEX) [26]. 
Fingolimod signifi cantly reduced annualized relapse 
rates (52% for 0.5 mg and 38% for 1.25 mg, both p 
< 0.0001) and MRI measures of infl ammation com-
pared with AVONEX. Safety data showed that the 
drug was generally well-tolerated, although there was 
an increased rate of localised skin malignancies and 
two fatalities from severe herpes infection. Other 
side-eff ects were a transient bradycardia and infre-
quent atrioventricular conduction blocks after the fi rst 
dose of fi ngolimod, minor increases in blood pressure 
persisting on therapy, and asymptomatic liver enzyme 
elevations. Macular oedema, mostly reversible within 
1 to 6 months after discontinuation of therapy [27], 
occurred in 3 patients on fi ngolimod. 
Based on the results for the 0.5 mg dose in the 
FREEDOMS and TRANSFORMS trials, fi ngoli-
mod (Gilenya®) was recently approved by the FDA 
for the treatment of patients with RRMS, and the 
Committee for Medicinal Products for Human Use 
(CHMP) adopted a positive opinion, recommending 
the granting of a marketing authorisation for Euro-
pean countries. 
Conclusion
A number of DMTs became available during the 
past 15 years which signifi cantly changed the thera-
peutic approach in multiple sclerosis (MS). Th ese con-
ventional DMTs with broad experience - interferon-
beta 1b, interferon-beta 1a, and glatiramer acetate are 
still partially eff ective and are not free from adverse 
eff ects. Th erefore, further development of DMT in 
MS has rapidly evolved over the last few years and 
continues to do so, leading to the additions to the 
treatment armamentarium, comprising immunosup-
pressive drug mitoxantrone, recently introduced anti-
body natalizumab and more recently, the sphyngosin-
1-phosphate receptor modulator fi ngolimod.
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